Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe
about
Vaccines for preventing influenza in healthy adultsEnhancing vaccine safety capacity globally: A lifecycle perspectiveCombining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013European decision-maker perspective with regard to influenza prevention policies.Frequently asked questions on seven rare adverse events following immunization.Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in EuropePandemic A/H1N1 2009 influenza vaccination, preceding infections and clinical findings in UK children with Guillain-Barré syndrome.Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in GermanyRisk of Guillain-Barré syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study.Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital diThe importance of influenza prevention for public health.Influenza vaccination coverage rate in children: reasons for a failure and how to go forward.[Guillain-Barré syndrome after exposure to influenza].Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study.Safety of AS03-adjuvanted split-virion H1N1 (2009) pandemic influenza vaccine: a prospective cohort studySafety of pandemic (H1N1) 2009 monovalent vaccines in taiwan: a self-controlled case series study.Data Extraction and Management in Networks of Observational Health Care Databases for Scientific Research: A Comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE Strategies.Use of population based background rates of disease to assess vaccine safety in childhood and mass immunisation in Denmark: nationwide population based cohort study.Clinical Features of Post-Vaccination Guillain-Barré Syndrome (GBS) in Korea.Comparatively low attendance during Human Papillomavirus catch-up vaccination among teenage girls in the Netherlands: Insights from a behavioral survey among parents.Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barré syndromeChanges in lymphocyte subsets in patients with Guillain-Barré syndrome treated with immunoglobulin.Seasonal influenza vaccination for children in Thailand: a cost-effectiveness analysisHospital Admissions, Transfers and Costs of Guillain-Barré Syndrome.The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination.Risk of Guillain-Barré syndrome after 2010-2011 influenza vaccination.Assessing the safety of influenza vaccination in specific populations: children and the elderly.The Innovative Medicines Initiative moves translational immunology forward.Dissecting the Role of Anti-ganglioside Antibodies in Guillain-Barré Syndrome: an Animal Model Approach.Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.Strategies in recommending influenza vaccination in Europe and US.Did the influenza A (H1N1) 2009 monovalent inactivated vaccines increase the risk for Guillain-Barré syndrome?Preparing for a potential A(H7N9) pandemic: lessons from the deployment of A(H1N1) pandemic vaccines.Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010.
P2860
Q24197955-18AACDD1-04CF-487E-B6E4-229CCCE27554Q26782451-E626D5AD-EB01-4876-9213-878FB17DC496Q26996499-E3EA682A-3B06-46B9-92A6-0DE6496400E3Q28654939-0F5D201D-19F9-4616-A8DA-3FF1DF1DE314Q30151954-F0F3F7FF-743D-402D-89DA-8AC3FAE71487Q30234430-FFE135C2-3FFF-40B5-AEF1-F07A5D3418CAQ30351998-4FBA887F-043E-42A6-879A-24CD27FEF89AQ30352329-1FFCC498-75C7-4ADC-93EA-EAD814481062Q30357675-4C09DB00-E0A0-4FDF-8E23-5934CD6907EAQ30359657-7254CA2C-D4D8-471C-803E-28B9E060CC30Q30362413-54DA03ED-45BF-4111-AD8E-6A94FD9B9B8BQ30374961-6EF127F5-8774-4421-BC2D-DE765E0978CCQ30388367-1F231BB5-4B44-493C-8F89-FDDD8C79CB7BQ30411857-D93A379C-A5B8-4F49-813A-9F7E2B1CD770Q30411868-8500FE65-5943-481F-B701-57FE8A5833C4Q30415924-30BB9D7B-DA6A-4E06-8280-7C61574AF86BQ30425209-E2542E93-33DB-449B-BC0F-AC72ED9CA5B3Q30426869-397D4C97-3BA6-45D5-9293-9BE8D415A1BBQ30428839-1866C842-BA2A-42BF-AF05-D0FD1971A44EQ31063299-BF700491-FE0D-49C7-BE29-FF6E28B9C749Q33403378-18CC9B54-1E4E-48D8-B794-5809D54B1DBCQ33770375-D7C75B6E-9982-4B84-B755-99C3104E0E80Q34322484-7807C48F-08D2-4441-82E1-2D051125167DQ34499848-A2C4F7FF-6AEB-4C72-A089-248EABCFA6E1Q35037338-E0B33DB6-BA06-47D4-AD2E-61F80BEDFE6DQ35331829-B2DB262F-0EC5-4D1F-B873-A2E2C7BB4154Q35642206-A5BB885E-3B52-4916-B12D-54A9D53B050DQ35918443-48A532B5-9CDE-4D1F-966D-38D605F31920Q36131193-32A5B809-A5B0-4687-8919-5D72AEB21BC5Q36174702-2E2404FA-5A90-4F78-A36D-C29C0952BE8AQ36882923-71AB8D61-A6F9-4E4E-AF99-0860CD16136BQ36902462-4B584AD2-2678-44FC-B00E-BC0EE0164AA0Q38045920-2BAA9ABE-1918-4488-AEDB-7CD9BF9C9ADCQ38093624-62497B08-C324-43CD-854E-DB7C9DE859C8Q38587703-6B484FC4-591A-4EB5-881D-FAB3061EE8D9Q38804897-1A63CEAD-04B2-4A28-83C0-192C758FFA92Q41996993-D823A75E-6E95-44B6-A0FF-C9E59C2C7987Q43700573-30EE42A7-2643-4491-967D-A5FAE045C2B2Q43753114-D32241F6-F688-4DFB-AE7B-488C48EBB3A1Q44927841-08DFC6A7-61AF-4704-93F6-35C79FDEA300
P2860
Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@ast
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@en
type
label
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@ast
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@en
prefLabel
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@ast
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@en
P2093
P2860
P921
P356
P1433
P1476
Guillain-Barre syndrome and ad ...... l case-control study in Europe
@en
P2093
Daniel Weibel
Jeanne Dieleman
Kari Johansen
Miriam Sturkenboom
Silvana Romio
VAESCO-GBS Case-Control Study Group
P2860
P356
10.1136/BMJ.D3908
P407
P577
2011-07-12T00:00:00Z